BBH
VanEck Biotech ETF
Set alert
- YTD
- +36.31%
- 1 year
- +44.86%
- Open
- 259.30
- Prev close
- 256.90
- Mkt cap
- 523.17M
- Vol
- 32.26K
- Avg vol
- 10.78K
- EPS
- 8.48
- P/E
- 30.42
- Div yield
- 0.00%
More statistics
- Low
- 256.52
- High
- 262.60
- Forward P/E
- 0.00
- Beta
- 0.00
- Short ratio
- 0.00
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 167.95
- 200-d avg
- 169.82
News
2 days ago zacks.com
ETFs That You May Consider Amid a Strengthening Biotech Outlook
Drug innovation, AI and rising M&A activity are boosting biotech optimism. Discover ETFs offering exposure to the sector.
1 week ago zacks.com
Why Healthcare ETFs Are Hovering Around One-Year Highs
Healthcare ETFs are hovering near 52-week highs as earnings prospects improve, clinical breakthroughs advance and GLP-1 demand expands. Explore five ETFs riding the rally.
1 week ago fool.com
Biotech Giants vs. Emerging Innovators: Which ETF Is the Better Buy?
Both of these ETFs look the part, but only one is truly the better buy for investors.
1 week ago zacks.com
Biotech ETF (BBH) Hits New 52-Week High
For investors seeking momentum, VanEck Biotech ETF BBH is probably on the radar. The fund just hit a 52-week high and has risen 41.1% from its 52-week low price of $176.30/share.
2 weeks ago businesswire.com
BBH Capital Partners Private Equity Exits The Granite Group
NEW YORK--(BUSINESS WIRE)--BBH Capital Partners Private Equity (BBHCP) today announced the successful exit of its investment in The Granite Group (Granite), a diversified distributor of plumbing and…
2 weeks ago fool.com
Better Biotechnology ETF: First Trust FBT vs. VanEck BBH
The First Trust NYSE Arca Biotechnology Index Fund has outperformed the VanEck Biotech ETF on a one-year basis and over the last five years. The VanEck Biotech ETF offers a lower expense ratio of…
2 weeks ago fool.com
Better Healthcare ETF: VanEck's Biotech-Focused BBH vs. State Street's XPH Targeting Pharma
BBH concentrates on 25 large-cap biotech leaders, while XPH diversifies across 62 pharmaceutical holdings. Both charge 0.35% annually, but their five-year returns diverged significantly.
1 month ago fool.com
Fidelity Healthcare ETF (FHLC) vs. VanEck Biotech ETF (BBH): Which Fund Is the Better Buy?
FHLC features a much lower expense ratio of 0.08% compared to 0.35% for BBH. BBH is a concentrated portfolio of just 26 stocks, while FHLC holds around 350 companies.
1 month ago zacks.com
Biotech ETFs to Buy as Cancer Drug Breakthroughs Accelerate
Biotech ETFs offer diversified exposure to oncology innovation as cancer funding surges and the global oncology drug market expands.
1 month ago zacks.com
Should You Invest in the VanEck Biotech ETF (BBH)?
Looking for broad exposure to the Healthcare - Biotech segment of the equity market? You should consider the VanEck Biotech ETF (BBH), a passively managed exchange traded fund launched on December…
1 month ago fool.com
VanEck Pharmaceutical ETF vs VanEck Biotech ETF: Which Fund Is Better for Drug Innovation Profits?
PPH offers higher income and lower volatility, while BBH delivers stronger growth but with deeper drawdowns.
2 months ago seekingalpha.com
BBH: Biotech's Next Growth Cycle Is Just Getting Started
VanEck Biotech ETF (BBH) is a Buy, offering concentrated exposure to leading biotech firms entering a new growth cycle. BBH's top holdings—Amgen, Gilead, and Vertex—drive capital appreciation through…
2 months ago fool.com
In Healthcare ETFs, Is iShares Pharma a Better Buy Than VanEck Biotech?
VanEck's concentrated 25-stock biotech play offers higher volatility, while iShares' broader pharma exposure delivered a 1.4% dividend yield and lower drawdown risk.
2 months ago fool.com
State Street XLV vs VanEck BBH: Which Healthcare ETF Is the Better Buy in 2026?
State Street Health Care Select Sector SPDR ETF offers a significantly lower expense ratio than VanEck Biotech ETF VanEck Biotech ETF focuses exclusively on 25 biotechnology stocks while State Street…
3 months ago fool.com
IHE vs. BBH: Which Healthcare ETF Is the Better Buy Right Now?
IHE pays a meaningfully higher dividend yield than BBH. BBH offers more concentrated exposure with 25 holdings, compared to 56 for IHE.
3 months ago fool.com
Invesco Healthcare ETF vs VanEck Biotech: Which ETF Will Deliver the Healthiest Returns for 2026?
Invesco S&P 500 Equal Weight Health Care ETF provides broader exposure with 60 holdings compared to the 25 positions in VanEck Biotech ETF VanEck Biotech ETF has a slightly lower expense ratio of…
3 months ago zacks.com
Should You Invest in the VanEck Biotech ETF (BBH)?
Designed to provide broad exposure to the Healthcare - Biotech segment of the equity market, the VanEck Biotech ETF (BBH) is a passively managed exchange traded fund launched on December 20, 2011.
3 months ago fool.com
Which is the Better Choice for Healthcare Investors? IYH or BBH?
iShares U.S. Healthcare ETF provides broader exposure with 100 holdings compared to the 25 found in VanEck Biotech ETF VanEck Biotech ETF has delivered higher recent total returns but carries…
3 months ago fool.com
BBH vs. XPH: Which Healthcare ETF Is Better for Beginners?
State Street SPDR S&P Pharmaceuticals ETF provides exposure to 65 companies compared to the 25 holdings in VanEck Biotech ETF. VanEck Biotech ETF has experienced a deeper maximum drawdown of almost…
3 months ago fool.com
FHLC vs. BBH: Which Healthcare ETF Is the Better Buy?
Fidelity MSCI Health Care Index ETF (FHLC) provides broad sector exposure with significantly lower fees than VanEck Biotech ETF (BBH). BBH focuses on just 25 holdings in the biotech space while FHLC…
6 months ago benzinga.com
Judge Hands Natera 30% Ongoing Royalty In MRD Patent Battle
Natera rises after a Delaware court grants a 30% ongoing royalty in its MRD patent battle with ArcherDx and Invitae.
7 months ago benzinga.com
Vertex's New Kidney Drug Delivers Big Trial Win, Stock Jumps
Vertex's kidney drug delivers a "clear win" in Phase 3. Clinical success and a 6% premarket jump signal a massive milestone for VRTX.
-
3 years ago benzinga.com
Mifepristone Abortion Pill Access in Limbo: Justice Department May Ask Supreme Court's Intervention
U.S. Attorney General Merrick Garland said that the Justice Department would file an appeal with the U.S. Supreme Court seeking to block the entirety of Kacsmaryk's order suspending the FDA approval…
-
3 years ago benzinga.com
Women's Reproductive Rights: US Court Preserves Access To Abortion Pill For Now, But With Tighter Rules
A U.S. federal appeals court has temporarily blocked a decision by a Texas judge to halt the FDA's approval of a widely used abortion drug.
-
3 years ago benzinga.com
New York and California Prepare For Potential Mifepristone Ban In Texas With Stockpiling Of Alternative Abortion Medications
New York and California are stockpiling an alternative abortion medication in case a Texas judge's order suspending the FDA approval of the primary drug, mifepristone, goes into effect later this…
-
3 years ago benzinga.com
Attorney Generals of Over 20 States Sound Alarm Over Suspension Of Abortion Med Approval: "Devastating Risks" Ahead
In a new court filing, the Democratic attorneys general for 23 U.S. states have reportedly warned that a federal judge's decision to suspend the FDA's approval of mifepristone "presents devastating…
-
3 years ago benzinga.com
FDA Withdraws Lone Premature Birth Drug Makena Over Lack of Proven Benefits
FDA Withdraws Lone Premature Birth Drug Makena Over Lack of Proven Benefits
-
3 years ago benzinga.com
US Judge Weighs Nationwide Ban On Abortion Pills
U.S. District Judge Matthew Kacsmaryk questioned President Joe Biden's administration lawyers on whether the federal regulatory approval of the abortion pill mifepristone was proper. The judge is…
-
3 years ago benzinga.com
FDA Takes Action To Restrict Unlawful Import Of Animal Tranquilizer 'Tranq' Or ''Zombie Drug'
FDA Takes Action To Restrict Unlawful Import Of Animal Tranquilizer 'Tranq' Or ''Zombie Drug'
-
5 years ago benzinga.com
5 Top ETFs With Exposure To Biogen
For the first time in 18 years, there was a new treatment for Alzheimer’s Disease approved by the FDA.
-
5 years ago benzinga.com
3 ETFs For AstraZeneca's $39B Alexion Pharmaceuticals Takeover
The biotechnology space is always fertile territory for mergers and acquisitions, and that theme was on display over the weekend when AstraZeneca (NYSE: AZN) announced a
-
10 years ago benzinga.com
Exclusive: SunTrust Managing Director Shares Thoughts On Drug Pricing, Impact On Biotech
Exclusive: SunTrust Managing Director Shares Thoughts On Drug Pricing, Impact On Biotech
-
10 years ago benzinga.com
Clinton's Proposal To Combat Drug Price Hikes
Clinton's Proposal To Combat Drug Price Hikes
-
12 years ago benzinga.com
Biotech And Natural Gas ETFs On A Roll
Biotech And Natural Gas ETFs On A Roll
-
13 years ago benzinga.com
ETFs to Watch September 9, 2013 (DES, EWJ, FXA)
ETFs to Watch September 9, 2013 (DES, EWJ, FXA)
-
13 years ago benzinga.com
Biotech Breakout Highlights Flawed ETF Thinking
Biotech Breakout Highlights Flawed ETF Thinking
-
13 years ago benzinga.com
A Look Ahead: This Week's ETFs to Watch
A Look Ahead: This Week's ETFs to Watch
-
13 years ago benzinga.com
ETFs to Watch August 6, 2013 (BSV, KOLD, THD)
ETFs to Watch August 6, 2013 (BSV, KOLD, THD)
-
13 years ago benzinga.com
ETFs to Watch August 1, 2013 (BSV, EWM, XRT)
ETFs to Watch August 1, 2013 (BSV, EWM, XRT)
-
13 years ago benzinga.com
Seasonal Trends: Three ETFs To Own In August
Seasonal Trends: Three ETFs To Own In August
-
13 years ago benzinga.com
Don't Forget About This Small-Cap Health Care ETF
Don't Forget About This Small-Cap Health Care ETF
-
13 years ago benzinga.com
Interesting Similarities Among 2013's Top-Performing ETFs
Interesting Similarities Among 2013's Top-Performing ETFs
-
13 years ago benzinga.com
Under The Hood: An Unheralded Biotech ETF
Under The Hood: An Unheralded Biotech ETF
-
14 years ago benzinga.com
Investors Cheating Themselves by Focusing on Largest ETFs
Investors Cheating Themselves by Focusing on Largest ETFs
-
14 years ago benzinga.com
Argument For Low Volume ETFs Gains Steam
Argument For Low Volume ETFs Gains Steam
-
14 years ago benzinga.com
ETF Winners that Could Keep Their Momentum (EPHE, FBT, XHB)
ETF Winners that Could Keep Their Momentum (EPHE, FBT, XHB)
-
14 years ago benzinga.com
Arena Approval Boosts Biotech ETFs (ARNA, IBB, XBI)
Arena Approval Boosts Biotech ETFs (ARNA, IBB, XBI)